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Prescription Drug Communication Strategies: A Comparative Analysis of 
Physician Attitudes in Europe, the Middle East and the Far East  
 
ABSTRACT  
 
Research into direct-to-consumer (DTC) advertising of prescription drugs is extensive 
in individualistic cultures. In contrast, using Hofstede’s classification to select 
representative collectivist countries in high potential regions and conducting surveys 
of 308 physicians in Greece, the United Arab Emirates and Taiwan, this research 
investigates physician attitudes towards the value of drug manufacturers’ physician- 
and consumer-targeted communication strategies. The analysis reveals that 
physicians are satisfied with physician-targeted communication strategies and greatly 
value two-way interactive approaches, though they have significantly differing 
attitudes across cultures towards the likely impacts of DTC advertising, with Greek 
physicians the most opposed. They generally support unbranded disease awareness 
campaigns though. The research findings thus suggest that planned value creation for 
manufacturers and consumers through DTC advertising conflicts with the value 
delivery for the intermediary physician, which delays the expansion of this advertising 
policy.  
Keywords: Direct-to-consumer advertising, Drug marketing, International, Value 
creation, Value delivery, Advertising ethics. 
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This research considers several features of value creation and value delivery 
(Lindgreen and Wynstra 2005) in the healthcare marketplace, with an emphasis on the 
complexity of creating and delivering value in a multiple stakeholder environment 
that includes both profit-oriented and not-for-profit motives. The drug market 
comprises the manufacture of products designed to treat consumers (profit motive) 
but also involves a key intermediary, namely, the physician (generally not-for-profit, 
with regard to pharmaceuticals). The relationships that constitute this marketplace 
include those between drug manufacturers and physicians, between physicians and 
consumers and, with the advent of direct-to-consumer (DTC) advertising of 
prescription drugs, between manufacturers and consumers.  
 
Drug manufacturers, in their efforts to increase sales (and provide value to 
shareholders), attempt to create and deliver value to consumers by advertising directly 
to them. Manufacturers assert that such advertising increases consumers’ healthcare 
knowledge, encourages dialogue with physicians and enhances the recognition and 
treatment of undiagnosed illnesses (Bonaccorso and Sturchio 2002; Mitka 2003). This 
policy seems to garner support from end-user groups, at least in the United States and 
United Kingdom (Kucharsky 2005; Lowery 2003; Reast, Palihawadana and Shabbir 
2008). However, the approach has proven less popular among an important 
intermediary: physicians. Prior research that surveys physicians in New Zealand, the 
United States and United Kingdom indicates their general opposition to DTC 
advertising. If anything, physicians perceive that DTC advertising destroys rather than 
creates value (Mitka 2003; Thomaselli 2003; Yuan and Duckwitz 2002). This study 
acknowledges these responses, as well as the ongoing calls for more research into 
how different value chain actors create and deliver value for customers (Lindgreen 
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and Wystra, 2005), and therefore provides a comparative investigation of DTC 
advertising across diverse cultures located in mainland Europe, the Middle East and 
Asia (Reast and Carson 2000; Reast, Palihawadana and Spickett-Jones 2004). 
 
In many countries, DTC advertising of prescription drugs is banned (Watson 2002). 
The initiation of such advertising in the United States in the early 1980s and in New 
Zealand in the 1990s prompted sustained ethical debates (Hensley and Vranica 2004; 
Lee, Salmon and Paek 2007), as well as vast communications budgets. Drug brand 
owners were responsible for advertising expenditures of approximately $9.4 billion 
between 1996 and 2001 (IMS Health, 2002), and DTC advertising has contributed 
significantly to the struggling U.S. media market (Thomaselli 2006). However, even 
in the U.S. market, calls for significant regulatory restrictions have followed the 
market withdrawals of high-profile DTC advertising power brands, such as Vioxx 
(Merck) and Bextra (Pfizer), due to alarming safety concerns (Edwards 2005). The 
perceptions of overly aggressive DTC advertising strategies and the potential damage 
to corporate reputations (Wielondek 2005) have led some manufacturers to signal 
their intention to reduce their above-the-line expenditures (Arnold 2005). Yet despite 
these issues and criticisms, consumer support for DTC advertising appears resilient 
(Dolliver 2005; Kucharsky 2005), with 70 percent of U.S. consumers claiming that 
they support a manufacturer’s right to advertise directly to consumers. 
 
Several variables may influence the likely international expansion of DTC 
advertising, such as increased calls for more drug information available to consumers, 
virtually unlimited international access to drug manufacturers’ U.S.-targeted Web 
sites, increasing e-retailing of prescription drugs and lobbying by manufacturers 
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(Rendon 2003). Therefore, the introduction of DTC advertising is being actively 
considered in Canada (Kucharsky 2005) and Australia (Smith 2007), and despite 
opposition to full DTC advertising in Europe (Watson 2002), unbranded drug 
advertising is increasing in this market. 
  
As an issue of major economic and ethical significance, DTC advertising has 
prompted extensive research, especially in U.S. and New Zealand markets. This 
research investigates both consumers’ (Alperstein and Peyrot 1993; Pines 1998) and 
physicians’ (Petroshius, Titus and Hatch 1995; Yuan and Duckwitz 2002) attitudes 
regarding the ethics (Hensley and Vranica 2004; Lee et al. 2007), benefits (Desselle 
and Aparasu 2000) and issues (Mintzes et al. 2002; Prince 2003) associated with DTC 
practices. However, other than a few studies in Australia (Miller and Waller 2004) 
and the United Kingdom (Lowery 2003; Reast and Carson 2000; Reast et al. 2008; 
U.K. Consumers Association 2002), little research notes responses by consumers or 
physicians to DTC advertising in the substantial drug markets of mainland Europe 
(which accounts for more than one-third of worldwide drug sales), the Middle East or 
the Far East.  
 
The global healthcare market outside of the United States, New Zealand and the 
United Kingdom is vast, worth some US$167 billion in Europe, over US$7 billion in 
the Middle East and more than US$50 billion in South and East Asia (IMS, 2005). 
Furthermore, the three markets that have garnered existing research attention all are 
individualistic cultures (Hofstede 1991), with relatively similar cultural profiles (see 
Appendix I). Considering the powerful influence of culture in many product and 
service domains (Yeniyurt and Townsend, 2003), responses to DTC advertising seem 
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likely to differ in countries whose cultural profile differs. Therefore, and considering 
possible bridgehead markets for the expansion of DTC advertising, we select three 
markets for further research. All three markets can classified as collectivist cultures, 
with low individualism scores and broadly similar cultural profiles (see Appendix I). 
However, DTC advertising is not currently permitted in these three markets. 
 
As one of the selected countries, Greece provides a representation of Hofstede’s 
European Country profile and the cultural profile of Southern European countries, 
which also include Spain and Portugal (Hofstede 1991). It contains one of the fastest 
growing healthcare markets in Europe and is the eighth largest of the 27 EU members. 
We also select the United Arab Emirates as a representative of the Arab Countries 
noted by Hofstede (together with Egypt, Iraq, Kuwait, Lebanon, Libya and Saudi 
Arabia), because it reflects the cultural profiles within this region. The healthcare 
market growth rate in the United Arab Emirates is almost 8 percent, well above the 
regional average. Finally, the collectivist Taiwanese culture is highly representative of 
Hofstede’s Asian Countries profile, broadly similar to mainland China and highly 
representative of other Asian countries such as Indonesia, South Korea and Thailand. 
Therefore, all three countries are collectivist cultures, with similar Hofstedian 
profiles, and representative of their local regions. In turn, they provide useful and 
relevant areas for research and potential bridgeheads for DTC advertising into 
Southern Europe (Greece), the Middle East (United Arab Emirates) and the Far East 
(Taiwan). The profiles for these three selected markets seem very similar, but of 
course, they are not identical on all measures. For example Greece records a very high 
uncertainty avoidance score (112) relative to the United Arab Emirates (68) and 
Taiwan (69).  
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Finally, this study addresses a critical research gap and provides an independent, 
exploratory evaluation of physicians’ attitudes to DTC advertising in mainland 
Europe (Greece), the Middle East (United Arab Emirates) and the Far East (Taiwan). 
Across these various representative international markets, this study pursues three 
main research objectives: to establish physician attitudes towards the value of 
physician-targeted versus consumer-targeted communications; to assess the level of 
acceptance, and perceived impacts, of DTC advertising amongst physicians; and to 
assess physician responses to unbranded disease campaigns. 
 
LITERATURE REVIEW AND HYPOTHESES 
Our review of DTC advertising, though comprehensive in nature, is structured to 
reflect our three main research questions. Most prior research inevitably occurs in the 
only two branded DTC advertising markets in the world, the United States and New 
Zealand, though the literature base also has been supplemented by research from the 
United Kingdom. (We provide a summary of the key physician-based empirical 
studies of DTC advertising in Appendix II.) For this review, we consider physicians’ 
prior attitudes towards physician-targeted and consumer-targeted communications, 
preferences for specific types of communications from drug manufacturers, attitudes 
regarding the ethics and impacts of DTC advertising and attitudes towards unbranded 
disease awareness campaigns. 
 
Physician- versus consumer-targeted communications 
Petroshius et al. (1995), who measure the general attitudes of U.S. physicians towards 
physician- and consumer-targeted communications, find a preference, particularly 
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amongst general practitioners, for the former. Although U.S. medical opinion 
appeared supportive of the value of DTC advertising in the mid-1990s (Petroshius et 
al. 1995), it may have become more negative over time; by 1997, a survey of U.S. 
family physicians indicated 80 percent of respondents viewed DTC advertising as a 
poor idea (Kravitz 2000; Mitka 2003). An IMS Health survey of 2,300 physicians also 
showed a 52 percent disapproval rating (Yuan and Duckwitz 2002). On balance, it 
appears that in recent years, more U.S. physician surveys have come to oppose than 
support DTC advertising (Mitka 2003; Thomaselli 2003; Yuan and Duckwitz 2002).  
 
The U.K.-based research also has shown a consistent preference for the ethics of 
physician-targeted rather than consumer-targeted communication (Lowery 2003; 
Reast and Carson 2000; Reast et al. 2004, 2008). These findings mirror the concerns 
about DTC advertising expressed by the British Medical Association (2001), the 
professional body that represents physicians in the United Kingdom.  
 
In New Zealand, though the two professional bodies representing physicians have 
expressed cautious support for the continuation of DTC advertising, grass-roots 
physician polls (MacKiven 1999) and the top two medical schools (Scrip 2003) accept 
physician-targeted communication but have condemned the practice of consumer-
targeted communication. 
  
Research amongst physicians therefore leads us to hypothesise:  
H1: Physicians from Greece, the United Arab Emirates and Taiwan 
significantly prefer the ethics of physician-targeted rather than consumer-
targeted communication for the advertising of prescription drugs 
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Petroshius and colleagues (1995) also indicate that the preferred advertising, that is, 
directed at physicians rather than consumers, influences the prescribing decisions U.S. 
physicians make. Research in the United Kingdom (Reast et al. 2004) suggests that 
physicians prefer types of communication with drug companies that give them the 
opportunity for dialogue and discussion (Williams and Hensel 1991).  
 
Previous research therefore implies that detailing or discussions with sales 
representatives (Soumerai and Avorn 1990), conversations during clinical meetings, 
specific drug-related or ailment-related conferences (Evans and Beltramini 1986) or 
even social events might be preferable to one-way communication with drug 
manufacturers (Williams and Hensel 1991). According to the limited amount of extant 
research available, physicians tend to attribute less value to impersonal information 
sources, such as physician-targeted advertising (Avorn, Chen and Hartley 1982), 
direct mail (Shearer, Gagnon and Eckel 1978) and email campaigns than they do to 
other forms of more personalised information (Williams and Hensel 1991). Such 
preferences for two-way over one-way communications appear to support the ‘high-
quality communications’ label often applied to two-way communications (Grunig and 
Hunt 1984). As an exception, medical journal articles represent a one-way, 
impersonal information source, yet prior research (Roberts 1987) indicates that these 
non-commercial sources tend to be perceived as welcome and valued information 
sources by physicians. 
 
Therefore, input from research amongst physicians suggests:  
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H2: Physicians from Greece, the United Arab Emirates and Taiwan 
significantly prefer two-way rather than one-way (with the exception of 
journal articles) communications with drug companies. 
 
The impacts of DTC advertising: Value enhancing? 
Debates about the impacts of branded DTC advertising generally have centred on 
impacts on patient–physician relationships, patient behaviours and concerns about 
communication strategies. First, in terms of the impacts on consumer–physician 
relationships, Peyrot and colleagues (1998) suggest that consumer awareness of DTC 
advertising activity may be associated with greater drug knowledge and more 
discussion with physicians relating to treatment. A U.S. Food and Drug 
Administration (FDA) survey also shows that increased DTC advertising prompts 
dialogue between physicians and consumers (Mitka 2003), which leads to stronger 
relationships between physicians and consumers (Bonaccorso and Sturchio 2002). Yet 
persons who are highly aware of advertising may not request specific drugs, due to 
concerns that this would annoy their physician (Peyrot et al. 1998). In contrast, 
Mechanic (1996), building on prior research by Perri and Nelson (1987), argues that 
an increased sense of consumerism in the physician–patient interaction might 
undermine their relationship. Potential conflicts might emerge in the relationship 
between physician and consumer, resulting from pressures to prescribe advertised 
drugs (Foley and Gross 2000; Mintzes et al. 2002; Prince 2003) or patients who may 
consider switching physicians who deny their drug requests (Kravitz 2000).  
 
Second, researchers note the impact of DTC advertising on the numbers of consumer 
requests for medication and visits to the physician (e.g., Reast and Carson 2000). Are 
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additional visits beneficial for consumers seeking advice from their physicians (Aikin, 
Swasy and Braman 2004)? Are ‘new illnesses’ (Desselle and Aparasu 2000) being 
recognised and treated as a result of consumers’ contact with DTC advertising 
(Bonaccorso and Sturchio, 2002)? Conversely, DTC advertising might be creating 
superfluous visits and drug requests, both of which have negative time and cost 
implications for physicians, patients and the economy in general (Prince 2003). 
Although some research implies that DTC advertising is educational and informative 
for consumers (Alperstein and Perrot 1993; Perri and Nelson 1987; Yamey 2001), 
other work indicates that it can result in patient confusion (Foley and Gross 2000). 
 
Third, U.S. research highlights problems associated with biased, incomplete or 
misleading advertising (Koerner 1999). An  FDA survey reveals that 65 percent of 
physicians believe their patients confuse the relative risks and benefits of drugs that 
appear in DTC advertising (Aikin et al. 2004). Also, the U.K. Consumers Association 
(2002) reveals that consumers express scepticism about the motives of drug 
manufacturers and their commitment to providing unbiased, reliable information 
about drugs or their side effects in their advertisements.  
 
Therefore, we hypothesise overall: 
H3: Physicians from Greece, the United Arab Emirates and Taiwan are 
negatively predisposed in their perceived impacts of branded DTC 
advertising.  
Attitudes towards unbranded disease awareness campaigns 
Because most U.S. research regarding DTC advertising concentrates on branded 
communication activity, little work pertains to unbranded disease awareness 
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campaigns. However, among U.K. physicians, Lowery (2003) finds an increasing 
majority who are supportive of unbranded approaches to consumer advertising; the 
campaigns also appear to have a mildly positive effect on patient traffic. A relatively 
small core of physicians remains hostile to such communications activities, as 
represented by recent European physician boycott actions of treatments promoted in 
unbranded disease awareness campaigns (Sheldon 2002). Similarly, Reast and 
colleagues (2004) find that though physicians are still mildly negative, they appear 
significantly more positive about unbranded disease awareness campaigns than about 
branded DTC advertising campaigns.  
 
On the basis of literature pertaining to unbranded DTC advertising campaigns, we 
hypothesise: 
H4: Physicians from Greece, the United Arab Emirates and Taiwan are 
positively disposed towards unbranded disease awareness campaigns. 
 
METHODOLOGY 
Physician attitude study 
This study employs scales from existing, comprehensive survey instruments used in 
prior DTC advertising research (Reast and Carson 2000; Reast et al. 2004, 2008). 
These instruments reflect key variables identified by drug communication studies 
(e.g., Alperstein and Peyrot 1993; Avorn et al. 1982; Petroshius et al. 1995; Shearer et 
al. 1978; Soumerai and Avorn 1990). The English-language instrument remains the 
same for the Greek respondents and is subject to forward- and back-translations for 
the United Arab Emirates and Taiwan samples, to ensure equivalence. The 
questionnaire consists mainly of a series of Likert-scaled items (1 = Strongly agree, 7 
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= Strongly disagree); we pre-tested it with 10 physicians from each region prior to the 
full sample collection. The scales used for the physician questionnaire instrument 
appear in Appendix III. The respondents provide demographic information, as well as 
their attitudes towards the relative value of physician-targeted communication 
approaches, ethics of physician-targeted versus consumer-targeted communication, 
likely impact of DTC advertising and unbranded disease awareness campaigns.  
 
Physicians attending symposia in Greece, the United Arab Emirates and Taiwan 
constitute the subject pools. The Greek sample was collected in Thessalonika (second-
largest Greek city), that for the United Arab Emirates was gathered in Dubai (largest 
United Arab Emirates state) and the Taiwanese sample came from a meeting in Taipei 
(capital city). To complete the self-administered questionnaire, physicians attending 
two-day regional or national (Taiwan) physician meeting were asked to spend 10–15 
minutes and return the questionnaire to the researcher prior to leaving the meeting. 
The initial sample was gathered on the first day of each symposium, with a follow-up 
sample collected from non-responders on the second day. We find no significant 
differences between responses and thus assert that non-response bias is not a 
significant concern for this study (Armstrong and Overton 1977). 
 
A total of 308 physicians (100 in Greece, 105 in the United Arab Emirates and 103 in 
Taiwan) participated, with an overall response rate of 52 percent across the three 
markets (see Table 1). The samples gathered for each market are comparable to those 
obtained in U.S. and U.K. physician surveys (Petroshius et al. 1995; Reast and Carson 
2000; Reast et al. 2004). Physicians often are accustomed to receiving incentives for 
taking part in commercial research, but the academic nature of this study generally 
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prevented requests for such incentives, nor were any provided. The level of physician 
interest in the subject matter appears to have been a motivator for engaging in the 
research. 
…Place Table 1 about here… 
RESULTS AND DISCUSSION 
The sample collected, representative of the physician populations for the respective 
country, reveals the demographic characteristics outlined in Table 2.  
…Place Table 2 about here… 
According to H1, physicians from the three countries prefer physician-targeted to 
patient-targeted marketing communications for prescription drugs. The results in 
Table 3 confirm that physicians from all regions have a significant preference for 
physician-targeted relative to consumer-targeted communications (p = .000 for all 
regions), in support of H1. 
…Place Table 3 about here… 
Although they consistently prefer the ethics of physician-targeted communications, 
the physicians display a large and significant difference in attitudes regarding the 
ethics of consumer-targeted advertising. Greek physicians in particular believe very 
strongly (  = 5.80, SD = 1.770) that such an approach is unethical, whereas 
physicians from the United Arab Emirates mildly accept these ethics (  = 3.50, SD = 
1.974). These significantly different perspectives may reflect the existing negative 
response to DTC advertising expressed within the EU Parliament (Watson 2002) and 
drug manufacturer boycotts by mainland European physicians (Sheldon 2002), which 
likely have greater effects on the Greek respondents. Their negative response also 
may reflect the relatively high uncertainty avoidance score of Greece (Hofstede 
1991), which suggests Greek people try to avoid change because it causes them 
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disquiet. The mean score of 5.80 (SD = 1.770) for Greek physicians is consistent with 
findings from prior research amongst U.K. physicians, who record a mean of 5.69 on 
the same scale (Reast et al. 2004). No other published European evidence is available 
for comparison.  
 
The mildly positive response to DTC advertising by United Arab Emirates physicians 
may reflect their close affiliations with the U.S. physician community. Many United 
Arab Emirates health professionals benefit from U.S. university training (UAE 
Embassy, 2009). For example, Harvard Medical School has a campus in Dubai, and 
John Hopkins University’s medical school and hospital maintains contracts within the 
United Arab Emirates’ hospital system. 
 
In H2, we posited that physicians from the three countries would prefer interactive, 
two-way communications rather than one-way communication methods (cf. published 
research articles in journals) from drug companies. The results in Table 4 confirm, at 
an aggregate level, that physicians from all regions significantly prefer two-way 
interactive communications over one-way communications (p = .000 for all regions).  
…Place Table 4 about here… 
In addition to this general support for H2, physicians from all three countries 
consistently value the opportunity for two-way communication (Grunig and Hunt 
1984), whether with the sales representative, at clinical study meetings or at 
manufacturer-sponsored conferences. Fairly universally, and in rank order, clinical 
study meetings (  = 2.49, SD = 1.384) appear as most valuable, followed by sales 
representative visits and sponsored conferences, which earn similar ratings (  = 2.63, 
SD = 1.344;  = 2.83, SD = 1.519, respectively). The only exception to the positive 
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ratings for two-way communications methods refers to social events (overall  = 4.01, 
SD = 1.720), which appear less valuable than the more formalised two-way 
communication. One-way, non-interactive communications, such as adverts, direct 
mail or emails, provoke less favourable responses, though none is highly negative. 
With regard to detailed responses to one-way communications, research results 
published in journals (  = 2.48, SD = 1.415) are listed as most valuable by all 
respondents (mean response is similar to that for the two-way clinical study 
meetings), followed by adverts in magazines (  = 3.82, SD = 1.677), mail shots (  = 
4.02, SD = 1.839) and then emails (  = 4.22, SD = 1.976) as less favourably rated 
methods. 
  
Although research results published in medical journals are technically a one-way 
communication format, they prompt favourable responses because they represent 
more credible and thus valuable information sources (compared with advertising in 
journals). These articles have been subject to peer review, and they encourage 
dialogue of sorts through responses to the publishing journal. This result aligns 
closely with prior research findings pertaining to the usefulness of research articles in 
journals (Reast et al. 2004; Roberts 1987; Williams and Hensel 1991), as well as with 
H2. 
 
We also proposed that physicians from all three countries would be negatively 
disposed to the ethics and ethics-related impacts of DTC advertising. Consistent with 
the findings from Table 3, as well as their attitudes towards the ethics of DTC 
advertising, we find that physicians are not uniformly negatively disposed towards 
DTC advertising, so we cannot confirm H3. Specifically, Greek physicians are 
 18 
significantly more opposed to the introduction of DTC advertising (  = 5.44, SD = 
2.007) than are either Taiwanese (  = 3.92, SD = 1.509) or United Arab Emirates (  
3.80, SD = 1.555) physicians, who instead hold largely neutral attitudes.  
…Place Table 5 about here… 
We also consider the ethics-related impacts of DTC advertising and here find largely 
consistent results; Greek physicians again tend to hold more negative attitudes 
towards DTC advertising, whereas physicians from the United Arab Emirates tend to 
be much more supportive. All our respondents agree that DTC advertising leads to an 
increase in unnecessary prescribing, yet Greek physicians (  = 1.95, SD = 1.684) 
appear significantly more negative than their counterparts (p = .004, p = .000). 
Moreover, Greek physicians are significantly more likely to believe that DTC 
advertising undermines the role of the physician as a health specialist (  = 2.52, SD = 
2.027, p = .000) and to disagree with the idea that DTC advertising improves health 
education (  = 4.92, SD = 2.160, p = .000 and .004).  
 
Greek physicians, along with Taiwanese physicians, hold significantly stronger 
attitudes than their United Arab Emirates counterparts about the pressure that DTC 
advertising places on physicians to defend their decisions. Greek physicians also feel 
significantly more strongly that DTC advertising is unlikely to enhance consumer–
physician relationships (  = 4.97, SD = 2.042, p = .000 and .002). Interestingly, and 
perhaps inconsistently, all physicians agreed, and some strongly, that DTC advertising 
increases unnecessary prescribing, but they also are broadly neutral toward the idea 
that DTC increases patient visits to the physicians themselves; only Taiwanese 
physicians (  = 3.67, SD = 1.560) exhibit mild agreement with this statement.  
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Finally, consistent with the view of the Taiwanese physicians that DTC drives 
patients to them, these same physicians feel, significantly more strongly than either 
Greek or United Arab Emirates physicians (  = 3.39, SD = 1.388, p = .017 and .000), 
that DTC advertising increases the workload for physicians. 
 
The response of Greek physicians is significantly more negative about the likely 
impacts of DTC advertising than that of Taiwanese or UAE physicians, but it is 
largely in line with the views described among U.K. physicians (Reast et al. 2004). 
The only substantive differences relate to perceived increases in consumer traffic and 
physician workload, about which U.K. physicians are more negative. The results 
gained from physicians from the United Arab Emirates and Taiwan have no regional 
comparisons; we address them in greater depth in the conclusion. 
 
Finally, H4 states that physicians from all three countries should have a positive 
attitude towards the perceived impacts of unbranded disease awareness campaigns. 
The results in Table 6 do not confirm this claim, so we cannot offer support for H4. 
…Place Table 6 about here… 
At the aggregate level, with overall mean scores, the response to unbranded disease 
awareness campaigns can be described at best as neutral. Physicians perceive some 
mild, potentially positive impacts of the campaigns, including increases in patient 
visits (  = 3.36, SD = 1.610), increases in patient requests for medication (  = 3.72, 
SD = 1.511), improvements in patient knowledge (  = 3.67, SD = 1.677) and 
increased numbers of prescriptions for promoted categories (  = 3.72, SD = 1.794). 
However, when they respond in the context of other measures, they indicate that such 
campaigns likely generate unnecessary patient visits (  = 3.62, SD = 1.881), and they 
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are neutral when it comes to whether these campaigns will result in patients’ 
recognition of genuine ailments (  = 3.99, SD = 1.756) or just more confusion (  = 
3.92, SD = 1.820). Overall, they do not believe these campaigns will increase their 
workload though (  = 4.19, SD = 1.785). 
 
The responses from the different groups of physicians reveals no absolutely consistent 
pattern of results, though broadly speaking, Taiwanese and, to a lesser extent, Greek 
physicians tend to acknowledge a greater impact (both positive and negative), 
whereas those from the United Arab Emirates tend to perceive little impact of 
unbranded disease awareness campaigns. The results broadly match those found for 
U.K. physicians, though this latter group tends to be slightly more negative in 
perceiving that unbranded disease awareness campaigns encourage a high level of 
patient traffic (some unnecessary), more drug requests and greater patient confusion 
(Lowery 2003; Reast et al. 2004).  
 
Although we cannot confirm H4 for all groups of physicians, responses to the impacts 
of unbranded disease awareness campaigns appear marginally more positive than 
those to branded DTC advertising (Table 5), which again is consistent with previous 
research published in a U.K. setting (Lowery 2003; Reast et al. 2004).   
 
RESEARCH IMPLICATIONS 
Europe, the Middle East and the Far East  
Several implications for researchers, practitioners and public policymakers derive 
from this study, many of which relate to conflicts over the value creation and delivery 
associated with drug communication strategies. First, physicians value two-way over 
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one-way physician-targeted communication approaches (Reast et al. 2004; Williams 
and Hensel 1991), yet such approaches tend to be more expensive (e.g., sales rep 
visits at $250–300 per call), whereas many large drug firms are trying to cut back on 
their large sales forces. Some current relationship management initiatives also attempt 
to downgrade ‘lower value physicians’ and target them with less costly 
communication contacts or fewer customer touches. Cost reduction efforts tend to 
mean switching from expensive, face-to-face, two-way contacts to less expensive 
two-way contacts (e.g., telephony) or one-way contacts such as direct mail or email. 
Our research suggests many physicians will be unhappy about this decision, because 
they perceive the less expensive contacts as less valuable  and poorer quality. There is 
thus a clear conflict of interests: Manufacturers derive more value from the exchange 
(profitability) by switching to cheaper communications formats, but physicians 
perceive a loss of (informational and relationship) value with this policy. 
 
Second, with regard to DTC advertising and practitioners in the advertising industry, 
our research indicates the need to acknowledge the nature of the stakeholder 
environment within the global drug market, if manufacturers hope to work to change 
the communications policy framework. Following an approach that maximises 
manufacturer value (e.g., sales, profits, share price) and focuses on end-customer 
value (e.g., health education, dialogue with physicians, illness recognition), at the 
expense of the healthcare intermediary, may be short-sighted. Physicians represent an 
important and influential stakeholder group, and their prescribing decisions have 
important influences on drug company profits (Dimopoulou and Fill 2000). Greek 
physicians—and European physicians in general, it would appear—exhibit very 
negative attitudes towards both the concept and perceived value and impacts of DTC 
 22 
advertising. European physicians remain highly sceptical about its overall merits. Yet 
physicians in Taiwan and the United Arab Emirates appear broadly neutral to the 
ethics of and mildly positive about any proposed introduction of DTC advertising. 
They also are positive about several perceived impacts of DTC advertising, which 
implies they may offer the least resistance to its extension. If Taiwan is generally 
representative of physician attitudes within Asia and the United Arab Emirates 
provides a good representative of wider physician opinion in the Middle East, our 
research might be considered a breakthrough insight for drug brand owners.  
 
Third, drug brand owners have an opportunity to enhance the value of their current 
unbranded disease awareness campaigns worldwide and reassure stakeholders 
concerned about branded DTC advertising communications. Unbranded disease 
awareness campaigns, if well managed (ideally with physician and stakeholder input) 
can provide a positive showcase for how DTC advertising might work. 
 
Working with, rather than against, physicians, should help ensure that the campaigns 
adopt precise and appropriate targeting, offer improvements in consumer health 
education and illness recognition and produce few complaints about biased or 
misleading advertising copy. Such an approach also may encourage physicians and 
public policymakers to look more favourably on the policy.  
 
Fourth, physicians universally indicate their belief that DTC advertising will lead to 
an increase in unnecessary prescriptions; therefore, public policymakers should 
recognise the potential impacts on national drug budgets (Prince 2003). Regardless of 
whether DTC advertising drives beneficial visits to the physician or unnecessary 
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wastes of time, the outcome is likely to be increased costs for managing patients and 
the extra prescriptions generated. Policymakers should weigh the value of DTC 
advertising in terms of the increased awareness and treatment of genuine illness 
(particularly among men) against the costs of such as policy. 
The U.S. direct-to-consumer advertising market  
The advertising industry, especially in the United States, can play a role in calming 
the fears of key stakeholder groups. Many major, global advertising agencies enjoy a 
strong position that enables them to recognise the wider geographic policy 
implications of aggressive advertising strategies in current DTC advertising markets. 
It is in the interest of these agencies to guide clients towards more responsible 
communication strategies, with the knowledge that this approach should lead to at 
least partial geographic extension of DTC advertising.  
 
The research findings also suggest some specific guidance for the U.S. domestic 
market situation. For example, many drug companies have chosen a pull strategy and 
DTC advertising, yet the physician remains a critically important stakeholder for 
prescription sales (i.e., push strategy). In the end, it is the physician who decides to 
prescribe a particular drug. Because of the importance of this relationship, and given 
the widespread evidence of biased, incomplete or misleading U.S. advertising targeted 
at consumers, physician research panels should be integrated into the communication 
planning process for new campaigns. This approach could ensure that health 
educational value exists in the campaigns whilst simultaneously reducing any 
misleading or confusing advertising and concerns about the ‘medicalisation’ of trivial 
diseases. In addition, advertising practitioners should revisit consumer-based 
positioning and pre-test research that underpins their existing campaigns to confirm 
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they offer clarity and educational value, particularly for older consumers (Foley and 
Gross 2000), who are often heavy users of medication. 
CONCLUSIONS 
Partially because of the conflicts regarding the value being created and delivered to 
stakeholders in drug markets worldwide, many objections still remain to DTC 
advertising. Manufacturers appear to have put their own self-interest (i.e., sales and 
profitability) ahead of delivering value to consumers (healthcare knowledge), at the 
expense of physicians’ interests and value. Many physicians believe that DTC 
advertising is of dubious value to consumers who might be confused more than 
educated, to governments that must confront vastly increasing health budgets and to 
physicians whose relationships with manufacturers suffers and whose value and 
position gets undermined with consumers. If manufacturers want greater success from 
their DTC advertising expansion, they should work more closely with their partners 
(physicians) in the value delivery process they provide to consumers. If physicians 
feel undermined, pressured and threatened by DTC advertising, they are more likely 
to oppose its extension. 
 
Physicians from Greece, the United Arab Emirates and Taiwan generally support the 
ethics of physician-targeted communications relative to consumer-targeted 
communications, and they exhibit a consistent preference for the value of a two-way 
interactive approach. Greek physicians are strongly opposed to the ethics, introduction 
and likely value of DTC advertising. In stark contrast, physicians in Taiwan are 
relatively neutral towards these aspects, and physicians in the United Arab Emirates 
are mildly positive about the ethics of such a policy, while physicians in both these 
countries are mildly in favour of its introduction.  
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Unlike their colleagues in the United Arab Emirates and Taiwan, Greek physicians 
tend to view DTC advertising as a potential detriment to the relationship between 
physician and patient, which might undermine the value of the physician within this 
relationship. The other key difference between Greek physicians and their colleagues 
from the United Arab Emirates and Taiwan is the perception of little educational 
value for consumers associated with DTC advertising. Relatively consistently across 
the three countries, physicians think that DTC advertising should increase 
unnecessary prescribing and add pressure on the physician to defend his or her 
prescribing decisions. Of course, the responses from the different countries are not 
entirely clear-cut, but the results do tell the story of a more positive outlook by 
Taiwanese and United Arab Emirates physicians and a strong negative perspective 
adopted by Greek physicians. Their strong opposition to DTC advertising suggests 
that the Southern European drug market may be an unlikely source of the catalyst for 
EU acceptance of the policy within the foreseeable future. However, regions such as 
the Middle East and Asia may offer more amenable opportunities for the development 
of branded DTC advertising.  
 
Finally, unbranded DTC advertising provokes mildly positive or neutral responses in 
these three sample countries. Further extensions of these value-adding, unbranded 
disease awareness campaigns therefore seem possible, because all stakeholders—
manufacturers, consumers and physicians—appear to find value in them. 
Research limitations 
Greece, the United Arab Emirates and Taiwan, according to Hofstede’s cultural 
classifications, are representative of their respective geographic regions, and the 
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samples collected are representative of physicians within each market. However, this 
research is limited in its ability to represent the views of all physicians in Southern 
Europe, the Middle East and the Far East. The survey conducted also cannot explain 
the underlying concerns and motivations that drive the respondents’ attitudes towards 
drug communication strategies. Finally, this research does not address other major 
potential geographic markets, such as the Indian sub-continent. 
Further research 
Given the positive response to DTC advertising by physicians from the United Arab 
Emirates, the Middle East, with its total population of approximately 400 million 
(approaching EU population numbers) demands further investigation. Also, in 
response to the ideas about DTC advertising in Taiwan, further consumer and 
physician studies should be directed towards other Asian countries, with the goal of 
establishing the likelihood of acceptance of DTC advertising. China, whose 
population is projected to reach 1.44 billion by 2025, and India, with a projected 
population of 1.46 billion by 2025, may offer key prospects for DTC advertising 
expansion. Furthermore, the negative response to DTC advertising in the U.K. and 
Greek samples suggests that qualitative research with European physicians should 
attempt to understand their motivations and objections in more depth, as well as how 
these concerns might be addressed. 
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TABLES 
 
Table 1: Survey Distribution and Response Rate 
 
Physicians  Number of  Number of  Response Rate (%) 
   Surveys Distributed Surveys Completed  
 
Greek   205    100   49 
UAE   200    105   53 
Taiwanese  185    103   56 
 
Total Sample  590    308   52 
 
 
Table 2: Demographic Profile of Physicians 
 Age Profile % 
≤ 40 yrs   ≥ 40 
Gender Profile % 
Male     Female 
Experience Profile % 
≤ 10 ys   ≥ 11 yrs  
 
Greece 
United Arab Emirates 
Taiwan 
 
 
39     61 
47     53 
65     35 
 
73      27 
79      21 
92      8 
 
 
45     55 
52     48  
59     41  
 
 
Table 3: Physician Targeted versus Patient Targeted Communications 
Notes: 1 = Agree, 7 = Disagree. 
 
 
 
Ethics of physician 
and consumer 
targeted 
communications: 
Overall 
Physician 
Mean  
(Std Dev) 
 
Greek 
Physician 
Mean 
(Std Dev) 
n
1 
UAE 
Physician 
Mean 
(Std Dev) 
n
3
 
Taiwan 
Physician 
Mean  
(Std Dev) 
n
2
 
Sig. 
value 
for 
Levene 
Statistic 
Sig. Sig. 
Differences 
Between 
groups 
n
1
 n
2
 n
3
 
Promotion of Rx 
Drugs to Physicians 
is ethical (a) 
 
Promotion of Rx 
Drugs to Patients is 
ethical (b) 
 
t-value ( a versus b) 
 
p-value ( a versus b) 
 
2.75 
(1.565) 
 
 
4.48 
(2.040) 
 
 
-12.188 
 
.000 
2.90 
(1.856) 
 
 
5.80 
(1.770) 
 
 
-11.542 
 
.000 
2.52 
(1.447) 
 
 
3.50 
(1.974) 
 
 
-3.799 
 
.000 
2.87 
(1.353) 
 
 
4.17 
(1.627) 
 
 
-7.600 
 
.000 
.003 
 
 
 
.158 
.167 
 
 
 
.000 
 
 
 
 
n
2
 & n
1 
(.000)
 
n
2
 & n
3 
(.023)
 
n
1
 & n
3 
(.000) 
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Table 4: Physician Attitudes to One- and Two-Way Communications 
Notes: 1 = Strongly agree, 7 = Strongly disagree. 
 
 
Table 5: Perceived Impact of DTC Advertising 
Approval and 
Perceived Impact of 
DTC Advertising 
Overall 
Physician 
Mean  
(Std Dev) 
 
Greek 
Physician 
Mean 
(Std Dev) 
n
1 
UAE 
Physician 
Mean 
(Std Dev) 
n
3
 
Taiwan 
Physician 
Mean  
(Std Dev) 
n
2
 
Sig. value 
for 
Levene 
Statistic 
Sig. Sig. Differences 
Between groups 
n
1
 n
2
 n
3
 
DTC advertising 
introduction should be 
approved 
 
Consumer Impacts: 
Improve health 
education 
 
Increase patients visits 
to physicians 
 
Physician Impacts: 
Increase unnecessary 
prescribing 
 
Increase physicians' 
workload 
Increase pressure on 
4.38 
(1.855) 
 
 
 
4.04 
(1.820) 
 
4.04 
(1.822) 
 
 
2.76 
(1.856) 
 
3.96 
(1.828) 
3.20 
5.44 
(2.007) 
 
 
 
4.92 
(2.160) 
 
4.17 
(2.165) 
 
 
1.95 
(1.684) 
 
4.09 
(2.127) 
2.82 
3.80 
(1.555) 
 
 
 
4.17 
(1.478) 
 
4.29 
(1.654) 
 
 
3.59 
(2.083) 
 
4.40 
(1.812) 
3.97 
3.92 
(1.509) 
 
 
 
3.05 
(1.289) 
 
3.67 
(1.560) 
 
 
2.72 
(1.366) 
 
3.39 
(1.388) 
2.80 
.000 
 
 
 
 
.000 
 
 
.000 
 
 
 
.000 
 
 
.000 
 
.000 
.000 
 
 
 
 
.000 
 
 
.038 
 
 
 
.000 
 
 
.000 
 
.000 
n
2
 & n
1
(.000) 
 
n
1
 & n
3 
(.000)  
 
 
 
n
2
 & n
1 
(.000)
 
n
2
 & n
3 
(.000)
 
n
1
 & n
3 
(.004) 
n
2
 & n
3 
(.042) 
 
 
 
n
2
 & n
1 
(.004)
 
n
2
 & n
3 
(.001)
 
n
1
 & n
3 
(.000) 
n
2
 & n
1 
(.017)
 
n
2
 & n
3 
(.000) 
n
2
 & n
3 
(.000)
 
Current Communications 
Methods Are ‘Extremely Useful’ 
Overall 
Physician 
Mean  
(Std Dev) 
 
Greek 
Physician 
Mean 
(Std Dev) 
n
1 
UAE 
Physician 
Mean 
(Std Dev) 
n
3
 
Taiwan 
Physician 
Mean  
(Std Dev) 
n
2
 
Sig. 
value for 
Levene 
Statistic 
Sig. Sig. 
Differences 
Between 
groups 
n
1
 n
2
 n
3
 
Medical sales representative visit 
(Two-way) 
Clinical study meetings 
(Two-way) 
Conferences sponsored by drug 
company (Two-way) 
Social events 
(Two-way) 
Mean: All two-way 
communications (A) 
Research results in journals 
(one-way) 
Prescription drug advertisements in 
journals (one-way) 
Mail-shots 
(one-way) 
Email information from companies 
(one-way) 
Mean: All one-way 
communications (B) 
 
t-value ( A versus B) 
p-value ( A versus B) 
2.63 
(1.344) 
2.49 
(1.384) 
2.83 
(1.519) 
4.01 
(1.720) 
2.98 
(1.015) 
2.48 
(1.415) 
3.82 
(1.677) 
4.02 
(1.839) 
4.22 
(1.976) 
3.62 
(1.094) 
 
-11.139 
.000 
2.60 
(1.463) 
2.19 
(1.475) 
2.55 
(1.654) 
3.88 
(1.976) 
2.80 
(1.123) 
2.27 
(1.550) 
4.13 
(1.900) 
3.52 
(1.956) 
4.24 
(2.234) 
3.54 
(1.250) 
 
-6.399 
.000 
2.40 
(1.187) 
2.90 
(1.369) 
3.17 
(1.665) 
3.88 
(1.826) 
3.08 
(1.030) 
2.93 
(1.346) 
3.39 
(1.653) 
3.77 
(1.849) 
3.90 
(2.052) 
3.49 
(1.009) 
 
-4.285 
.000 
2.88 
(1.343) 
2.35 
(1.208) 
2.75 
(1.121) 
4.25 
(1.272) 
3.06 
(.861) 
2.22 
(1.232) 
3.92 
(1.369) 
4.75 
(1.460) 
4.53 
(1.546) 
3.85 
(.983) 
 
-9.379 
.000 
 
.184 
 
.417 
 
.000 
 
.000 
 
.016 
 
.095 
 
.000 
 
.001 
 
.000 
 
.077 
.039 
 
.000 
 
.011 
 
.202 
 
.090 
 
.000 
 
.006 
 
.000 
 
.069 
 
.038 
n
2
 & n
3
 (.030) 
 
n
2
 & n
3
 (.011) 
n
1
 & n
3
 (.001) 
n
1
 & n
3
 (.009) 
 
 
 
 
 
n
2
 & n
3
 (.001) 
n
1
 & n
3
 (.002) 
n
1
 & n
3
 (.005) 
 
n
2
 & n
3
 (.000) 
n
2
 & n
1
 (.000) 
 
 
n
2
 & n
3
 (.048) 
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physician to defend 
prescribing decisions 
 
Relationship Impacts: 
Undermine value of 
physician as health 
specialist 
Enhance patient-
physician relationship 
by encouraging more 
communication 
 
(1.816) 
 
 
 
3.37 
(1.910) 
 
4.18 
(1.907) 
 
(2.022) 
 
 
 
2.52 
(2.027) 
 
4.97 
(2.042) 
(1.900) 
 
 
 
4.08 
(1.983) 
 
4.10 
(1.830) 
(1.180) 
 
 
 
3.51 
(1.334) 
 
3.49 
(1.545) 
 
 
 
 
.000 
 
 
.000 
 
 
 
 
.000 
 
 
.000 
n
1
 & n
3 
(.000) 
 
 
 
n
2
 & n
1 
(.000)
 
n
1
 & n
3 
(.000) 
 
n
2
 & n
1 
(.000)
 
n
2
 & n
3 
(.043)
 
n
1 
& n
3 
(.002) 
Notes: 1 = Strongly agree, 7 = Strongly disagree.  
 
 
Table 6: Impact of Unbranded Disease Awareness Advertising 
Impact of Unbranded 
Disease Awareness 
Advertising 
Overall 
Physician 
Mean  
(Std Dev) 
 
Greek 
Physician 
Mean 
(Std Dev) 
n
1 
UAE 
Physician 
Mean 
(Std Dev) 
n
3
 
Taiwan 
Physician 
Mean  
(Std Dev) 
n
2
 
Sig. 
value 
for 
Levene 
Statistic 
Sig. Sig. 
Differences 
Between 
groups 
n
1
 n
2
 n
3
 
Lead to increases in patient 
visits 
Lead to increases in patient 
requests for medication 
Improve patients' 
knowledge 
Improve the Physician-
Patient Relationship 
Lead to confusion amongst 
patients 
Increased physicians’ 
workload 
Encourage unnecessary 
patient visits  
Result in increased Rx's for 
promoted categories 
Result in patient 
recognition of genuine 
ailments 
 
3.36 
(1.610) 
3.72 
(1.511) 
3.67 
(1.677) 
4.07 
(1.746) 
3.92 
(1.820) 
4.19 
(1.785) 
3.62 
(1.881) 
3.72 
(1.794) 
3.99 
(1.756) 
3.30 
(1.998) 
3.36 
(1.495) 
3.56 
(1.922) 
4.09 
(2.057) 
3.94 
(2.040) 
4.25 
(1.897) 
2.80 
(1.659) 
3.14 
(1.445) 
4.05 
(1.840) 
3.26 
(1.443) 
4.27 
(1.502) 
4.01 
(1.657) 
4.47 
(1.689) 
4.00 
(1.906) 
4.59 
(1.820) 
4.49 
(1.893) 
4.54 
(1.936) 
4.24 
(1.891) 
3.65 
(1.271) 
3.22 
(1.229) 
3.20 
(1.181) 
3.32 
(1.022) 
3.76 
(1.286) 
3.35 
(1.224) 
3.17 
(1.465) 
3.00 
(1.300) 
3.42 
(1.177) 
.001 
 
.246 
 
.005 
 
.000 
 
.007 
 
.012 
 
.036 
 
.000 
 
.001 
.446 
 
.000 
 
.040 
 
.003 
 
.815 
 
.002 
 
.000 
 
.000 
 
.059 
 
 
n
2
 & n
3 
(.001)
 
n
1
 & n
3 
(.002) 
n
2
 & n
3 
(.036)
 
 
n
2
 & n
3 
(.002) 
 
 
 
n
2
 & n
1 
(.038)
 
n
2
 & n
3 
(.001) 
n
2
 & n
3 
(.000)
 
 n
1
 & n
3 
(.000) 
n
2
 & n
3 
(.000)
 
 n
1
 & n
3 
(.000) 
n
2
 & n
3 
(.049) 
Notes: 1 = Strongly agree, 7 = Strongly disagree.  
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APPENDICES 
Appendix I: Hofstede’s Cultural Profiles 
Country Power Distance Individualism Uncertainty 
avoidance 
Masculinity 
Individualistic 
country profiles 
USA 
New Zealand 
Great Britain 
Collectivist sample 
Greece 
Arab Countries 
Taiwan 
Comparator 
countries 
Spain 
Iran 
China, Mainland 
 
 
40 
22 
35 
 
60 
80 
58 
 
 
57 
58 
80 
 
 
91 
79 
89 
 
35 
38 
17 
 
 
51 
41 
20 
 
 
46 
49 
35 
 
112 
68 
69 
 
 
86 
59 
35 
 
 
62 
58 
66 
 
57 
53 
45 
 
 
42 
43 
50 
Source: Hofstede (1991) 
 
 
Appendix II: IMS Data: World Drug Market Forecasts 2005–2010 
Geographic Area Project 2010 value 
US $ billion 
Assumed Growth Rate 
2005-2010 % 
Europe (EU) exc. U.K. 
Greece 
South East & East Asia 
Taiwan 
People’s Republic of China 
(PRC) 
Middle East 
United Arab Emirates 
North America 
United States 
Latin America 
Indian sub-continent 
African continent 
New Zealand 
166.8 
5.9 
52.6 
4.2 
27.0 
 
7.2 
.407 
365.4 
346.5 
38.8 
13.4 
11.1 
.802 
5.2 
6.0 
12.3 
5.5 
18.4 
 
5.7 
7.9 
6.5 
6.5 
5.9 
10.4 
6.4 
0.9 
Notes: Values based on ex-manufacturer prices using constant exchange rates. 
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Appendix III: DTC Advertising: Key Physician Research Studies 
  
Appendix IV: Source of scales used in prior research 
 
Scales utilised Prior use of Scale 
The promotion of prescription drugs to doctors is ethical Reast and Carson, 2000; Reast, Palihawadana and Shabbir, 2008 
Advertising prescription drugs directly to patients is ethical Reast and Carson, 2000; Reast, Palihawadana and Shabbir, 2008 
How do you rate the value to your work of the following types of 
communication conducted by drug companies? 
 Medical sales representative visit 
Reast, Palihawadana, and Spickett-Jones, 2004 
 
Reast, Palihawadana, and Spickett-Jones, 2004 
 Clinical study meetings Reast, Palihawadana, and Spickett-Jones, 2004 
 Conferences sponsored by drug company Reast, Palihawadana, and Spickett-Jones, 2004 
 Social events Reast, Palihawadana, and Spickett-Jones, 2004 
Research results in journals Reast, Palihawadana, and Spickett-Jones, 2004 
 Prescription drug advertisements in journals Reast, Palihawadana, and Spickett-Jones, 2004 
 Mail-shots Reast, Palihawadana, and Spickett-Jones, 2004 
 Email information from companies 
 
Reast, Palihawadana, and Spickett-Jones, 2004 
To what extent do you approve of the introduction of prescription 
drug advertising to the general public? 
Reast and Carson, 2000; Reast, Palihawadana and Shabbir, 2008 
To what extent do you agree that the following effects will result 
from the advertising of prescription drugs to the general public? 
 Improve health education 
Reast and Carson, 2000; Reast, Palihawadana and Shabbir, 2008 
 
Reast and Carson, 2000; Reast, Palihawadana and Shabbir, 2008 
 Increase patients visits to physicians Reast and Carson, 2000; Reast, Palihawadana and Shabbir, 2008 
 Increase unnecessary prescribing Reast and Carson, 2000; Reast, Palihawadana and Shabbir, 2008 
 Increase physicians' workload  Reast, Palihawadana and Spickett-Jones, 2004 
 Increase pressure on physician to defend prescribing 
decisions 
Reast and Carson, 2000 
Authors Objectives Methodology  Major Findings 
Petroshius et 
al. (1995) 
Relationship between 
physician attitude to DTC 
advertising: physician 
targeted ads; attention to 
ads; Rx writing habits; and 
response to patient requests.  
Self-administered questionnaire 
amongst a sample of 148 US 
physicians, and a questionnaire 
hand-delivered to 250 physicians’ 
offices.  
U.S. physicians are favourably disposed to the advertising of drug products to 
both consumers and physicians. Results suggest that physicians’ attitudes to DTC 
advertising ads are good predictors of: attention to the ads, writing prescriptions 
for advertised products, and responsiveness to patient requests.  
Reast and 
Carson 
(2000) 
Attitudes of GPs & hospital 
physicians towards DTC 
advertising.  
A total of 68 U.K. physicians: 35 
GPs and 33 Hospital physicians.  
While supportive of physician-targeted material, the sample opposed DTC 
advertising introduction, perceived that it would damage physician patient 
relationships, and perceived it to have many negatives.  
Lowery 
(2003) 
Attitudes of U.K. physicians 
towards DTC advertising, 
and physician and consumer 
attitudes towards current 
disease awareness 
campaigns. 
U.K. Survey of 203 GPs and 1050 
consumers. 
GPs reported generally negative attitudes to DTC advertising, with 75% opposing 
DTC advertising. A majority were positive about ‘disease awareness campaigns’.  
Aikin et al. 
(2004) 
To evaluate the effects of 
DTC advertising on the 
public health and on 
physician-patient interaction 
& behaviour. 
U.S. Federal Drugs 
Administration (FDA) survey of 
944 consumers.  
 
FDA survey of 500 physicians in 
2002 
Results indicated high levels of DTC advertising awareness. DTC advertising 
prompted information search, and low levels of DTC advertising prompted 
surgery visits and drug requests. 
Overall physicians were broadly divided regarding the impacts of DTC 
advertising, and whilst 86% of physicians reported that patients asked about a 
specific drug, almost 90% had the appropriate condition. 
Eagle and 
Chamberlain 
(2004) 
To investigate DTC 
advertising awareness, 
information search, surgery 
visits, drug requests and 
physician responses.  
General Physicians (262), 
Pharmacists (259), and Practice 
Nurses (418) in N.Z.  
1310 NZ consumers  
Almost 73% of respondents recalled seeing or hearing a DTC advertising, but just 
8-9% raised discussion with physician. Findings showed low levels of pressure 
being felt by physicians in their prescribing decisions.  
Reast, 
Palihawadana 
and Spickett-
Jones (2004) 
Assessing the attitudes of 
U.K. physicians towards the 
concept and likely impact of 
DTC advertising, and 
attitudes towards unbranded 
DTC advertising campaigns 
U.K. – 160 general practitioners 
and hospital physicians – 
questionnaire survey 
U.K. physicians are opposed to the concept and likely overall impact of branded 
DTC advertising campaigns, and also towards unbranded DTC campaigns 
Reast, 
Palihawadana 
and Shabbir 
(2008) 
Assessing the attitudes of 
U.K. physicians and 
Consumers towards DTC 
advertising campaigns 
U.K. – 168 physicians, 285 
consumers – questionnaire survey 
U.K. physicians are strongly opposed, and U.K. consumers are neutral towards the 
idea of DTC advertising of prescription drugs. Physicians were less negative 
toward unbranded campaigns, and consumers were mildly positive to these 
unbranded disease awareness campaigns. 
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 Undermine value of physician as health specialist Reast and Carson, 2000; Reast, Palihawadana and Shabbir, 2008 
 Enhance patient-physician relationship by encouraging 
more communication 
Reast and Carson, 2000; Reast, Palihawadana and Shabbir, 2008 
How would you rate the impact of unbranded ‘see your doctor’ 
advertising campaigns by drug manufacturers? 
 They will lead to increases in patient visits 
Reast, Palihawadana and Spickett-Jones, 2004; Reast, 
Palihawadana and Shabbir, 2008 
Reast, Palihawadana and Spickett-Jones, 2004; Reast, 
Palihawadana and Shabbir, 2008 
 They will lead to increases in patient requests for 
medication 
Reast, Palihawadana and Spickett-Jones, 2004; Reast, 
Palihawadana and Shabbir, 2008 
 They will lead to improved patients’ knowledge Reast, Palihawadana and Spickett-Jones, 2004; Reast, 
Palihawadana and Shabbir, 2008 
 They will improve the physician-patient relationship Reast, Palihawadana and Spickett-Jones, 2004; Reast, 
Palihawadana and Shabbir, 2008 
 They will lead to confusion amongst patients Reast, Palihawadana and Spickett-Jones, 2004; Reast, 
Palihawadana and Shabbir, 2008 
 They will increase physician workloads Reast, Palihawadana and Spickett-Jones, 2004; Reast, 
Palihawadana and Shabbir, 2008 
 They will encourage unnecessary patient visits Reast, Palihawadana and Spickett-Jones, 2004; Reast, 
Palihawadana and Shabbir, 2008 
 They will result in increased prescriptions for promoted 
categories 
Reast, Palihawadana and Spickett-Jones, 2004; Reast, 
Palihawadana and Shabbir, 2008 
 They will result in patient recognition of genuine 
ailments 
Reast, Palihawadana and Spickett-Jones, 2004; Reast, 
Palihawadana and Shabbir, 2008 
 
 
 
